Core Viewpoint - Huate Dain (000915) reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong operational performance and potential investment opportunities [1] Financial Performance - The company achieved a revenue of 432 million yuan in the third quarter, representing a year-on-year increase of 93.28% [1] - The net profit attributable to shareholders for the third quarter was 70.6 million yuan, showing a year-on-year growth of 110.42% [1] - For the first three quarters, the total revenue reached 1.603 billion yuan, with a year-on-year increase of 16.3% [1] - The net profit attributable to shareholders for the first three quarters was 408 million yuan, reflecting a year-on-year growth of 11.67% [1]

Financial Performance - For the first nine months of 2025, the company achieved operating revenue of CNY 1.603 billion, with a net profit attributable to shareholders of CNY 408 million, representing year-on-year growth of 16.30% and 11.67% respectively[4] - The pharmaceutical business generated operating revenue of CNY 1.578 billion and a net profit of CNY 757 million, reflecting increases of 16.77% and 9.64% compared to the same period in 2024[4] - In Q3 2025, the company reported operating revenue of CNY 432 million, a significant increase of 93.28% year-on-year, and a net profit of CNY 70.6 million, up 110.42% from the previous year[5] - The basic earnings per share for the first nine months of 2025 was CNY 1.7414, marking an increase of 11.67% compared to the same period last year[5] - Net profit for the period was ¥767,418,437.12, representing a 10.8% increase from ¥692,591,722.84 in the previous period[16] - Earnings per share (EPS) for the period was ¥1.7414, compared to ¥1.5594 in the prior period, reflecting a growth of 11.6%[16] Assets and Liabilities - The company's total assets as of September 30, 2025, were CNY 4.780 billion, a decrease of 3.06% from the end of the previous year[5] - The company's total current assets amount to ¥3,372,578,876.81, a decrease from ¥3,510,737,250.04 at the beginning of the period[12] - The total assets of the company are ¥4,779,984,839.06, down from ¥4,930,936,591.73[13] - The company's total liabilities amount to ¥473,747,067.84, an increase from ¥418,011,480.27[13] - Total liabilities increased to ¥573,205,007.48 from ¥518,499,753.28, indicating a rise of 10.6%[14] - The company's equity attributable to shareholders decreased by 2.08% to CNY 2.851 billion compared to the end of the previous year[5] - Total equity attributable to shareholders decreased to ¥2,851,053,959.18 from ¥2,911,651,440.88, a decline of 2.1%[14] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 955 million, representing a 70.50% increase year-on-year[5] - The net cash flow from operating activities was CNY 954,987,097.75, an increase of 70.4% compared to CNY 560,093,957.28 in the previous period[18] - Total cash inflow from operating activities amounted to CNY 2,654,451,852.64, up from CNY 2,015,317,935.16, reflecting a growth of 31.6%[18] - Cash outflow from operating activities was CNY 1,699,464,754.89, compared to CNY 1,455,223,977.88, representing an increase of 16.8%[18] - The ending balance of cash and cash equivalents was CNY 1,820,357,317.28, an increase from CNY 1,610,259,774.32[18] Expenses - Sales expenses for the first nine months of 2025 amounted to CNY 342.8 million, a rise of 37.13% compared to the same period in 2024, attributed to higher marketing activity costs and sales personnel bonuses[9] - The company experienced a 2118.27% increase in credit impairment losses, amounting to CNY 6.6 million, mainly due to the recovery of large overdue accounts[9] - Research and development expenses were ¥68,738,075.33, slightly up from ¥64,281,936.19 in the prior period[15] - The company recorded a tax expense of ¥131,540,958.88, which is marginally higher than ¥129,753,178.59 in the previous period[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,598[10] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[10] - The company has no preferred shareholders as indicated in the report[12] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 262.65% to CNY 203.7 million, primarily due to increased advance payments from customers[8] - The company reported a financial asset fair value change gain of ¥8,168,115.06, compared to ¥6,090,195.26 in the previous period[16] - Cash inflow from investment activities totaled CNY 2,012,895,539.01, down from CNY 2,186,690,952.50, indicating a decrease of 7.9%[18] - Cash outflow from investment activities increased to CNY 2,234,199,712.60 from CNY 2,081,136,231.58, marking a rise of 7.4%[18] - Cash flow from financing activities resulted in a net outflow of CNY -973,075,444.00, compared to CNY -1,090,241,186.50 previously[18]

Core Insights - The company reported a third-quarter revenue of 432 million, representing a year-over-year increase of 93.28% [1] - The net profit for the third quarter was 70.6 million, showing a year-over-year growth of 110.42% [1] - For the first three quarters, the total revenue reached 1.603 billion, with a year-over-year increase of 16.30% [1] - The net profit for the first three quarters was 408 million, reflecting a year-over-year growth of 11.67% [1]

山东华特达因健康股份有限公司 董事会薪酬与考核委员会工作规则 第一章 总则 第一条 为进一步建立健全公司董事(非独立董事)及高级管理人员的考核和 薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》《上市公司 治理准则》《上市公司独立董事管理办法》《公司章程》等规定，制定本工作规 则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要负责制定公司董事及高级管理人员的考核标准并进行考核，负责制定、审查 公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本规则所称董事是指在本公司领取薪酬的董事长、董事，高级管理 人员是指董事会聘任的总经理、财务总监、副总经理、董事会秘书及由总经理 提请董事会聘任的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，其中独立董事二名。 第五条 薪酬与考核委员会委员由董事长、过半数独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事担任，主任委员由 董事长提名，经董事会选举产生。 第七条 薪酬与考核委员会任期与董事会任期一致，委员任期届满，连选可 以连任。 ...

董事会提名委员会工作规则 第一章 总 则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董事管理 办法》《公司章程》及其他有关规定，公司特设立董事会提名委员会，并制定本 工作规则。 第二条 董事会提名委员会是董事会按照股东会决议设立的专门工作机构， 主要负责董事、高级管理人员的人选、选择标准、程序等事项向董事会提出建议。 第二章 人员组成 第三条 提名委员会成员为 3 人，由董事长和 2 名独立董事组成。 山东华特达因健康股份有限公司 第四条 提名委员会委员由董事长、过半数独立董事或者全体董事的三分之 一提名并由董事会选举产生。 第五条 提名委员会设主任委员 1 名，由独立董事委员担任，由董事长提名， 经董事会选举产生。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，则自动失去委员资格，并由董事会根据上 述规定补足委员人数。 第七条 股东关系管理部协助董事会秘书处理提名委员会的日常事务，包括 日常工作联络和提名委员会会议的组织筹备等。 第三章 职责权限 第八条 公司董 ...

山东华特达因健康股份有限公司 董事会审计与风险委员会工作规则 第一章 总 则 第五条 审计与风险委员会设主任委员一名，由独立董事中会计专业人士担 任，由董事长提名，经董事会选举产生。 第一条 为强化董事会决策功能，确保董事会决策的正确执行和对经理层的 有效监督，完善公司治理结构，根据《中华人民共和国公司法》《上市公司治理 准则》《上市公司独立董事管理办法》《公司章程》等规定，制定本工作规则。 第二条 董事会审计与风险委员会是董事会按照股东会决议设立的专门工作 机构，主要负责： （一）公司内、外部审计的沟通、监督和核查工作； （二）对经理层执行董事会决策等情况进行监督； （三）对经理层执行财会制度的情况等实施监督。 第二章 人员组成 第三条 审计与风险委员会由三名董事组成，其中独立董事二名，并有一名 为专业会计人士。 第四条 审计与风险委员会委员由董事长、过半数独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第六条 审计与风险委员会任期与董事会一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根据 上述规定补足委员人数。 第七条 审计与风险委员会下设审 ...

山东华特达因健康股份有限公司 董事会战略与投资委员会工作规则 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》《上市公司治理准则》 《上市公司独立董事管理办法》《公司章程》等规定，制定本工作规则。 第二条 董事会战略与投资委员会是董事会按照股东会决议设立的专门工作 机构，主要负责对公司中长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略与投资委员会由五名董事组成，其中应包括三名独立董事。 第四条 战略与投资委员会委员由董事长、过半数独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 战略与投资委员会设主任委员一名，由公司董事长担任。 (一) 对公司发展战略规划进行研究，提出公司战略发展的构想和中长期发 展战略建议，监控公司中长期发展战略和目标的执行情况，组织审查、检讨公司 的战略发展方向，适时提出战略调整计划； (二) 对按《公司章程》规定须经股东会、董事会批准的重大投资、融资方 案进行研究并提出建议； (三) ...

证券代码：000915 证券简称：华特达因 公告编号：2025-041 山东华特达因健康股份有限公司 第十一届董事会第五次会议决议公告 1.以 9 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公 司 2025 年第三季度报告》。 《公司 2025 年第三季度报告》已经公司第十一届董事会审计与 风险委员会审议通过。审计与风险委员会认为：公司编制的《2025 年第三季度报告》真实、准确、完整地反映了公司的财务状况和经营 成果，同意将报告提交公司董事会审议。 2.以 9 票同意 0 票弃权 0 票反对的表决结果，审议通过了"《审 计与风险委员会工作规则》修订案"。 3.以 9 票同意 0 票弃权 0 票反对的表决结果，审议通过了"《提 名委员会工作规则》修订案"。 4.以 9 票同意 0 票弃权 0 票反对的表决结果，审议通过了"《薪 酬与考核委员会工作规则》修订案"。 5.以 9 票同意 0 票弃权 0 票反对的表决结果，审议通过了"《战 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 ...

Core Viewpoint - Huate Dain's stock price has seen a continuous increase over the past four days, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Overview - Huate Dain Health Co., Ltd. is located in Jinan, Shandong Province, and was established on June 26, 1993, with its listing date on June 9, 1999 [1]. - The company's main business involves environmental protection and the pharmaceutical industry, with pharmaceutical products accounting for 98.59% of its revenue [1]. Group 2: Stock Performance - As of October 24, Huate Dain's stock price is at 32.83 CNY per share, with a trading volume of 116 million CNY and a turnover rate of 1.50%, resulting in a total market capitalization of 7.693 billion CNY [1]. - The stock has experienced a cumulative increase of +Inf% over the last four days [1]. Group 3: Shareholder Information - A fund under China Merchants Fund has entered the top ten circulating shareholders of Huate Dain, holding 2.1211 million shares, which is 0.91% of the circulating shares [2]. - The fund, China Merchants Pharmaceutical Health Industry Stock (000960), has achieved a year-to-date return of 22.88% and a one-year return of 10.33% [2]. Group 4: Fund Performance - The same fund holds Huate Dain as its fifth-largest heavy stock, with 2.1211 million shares accounting for 5.36% of the fund's net value [3]. - The fund manager, Li Jiasun, has a tenure of 10 years and 271 days, with the best fund return during this period being 128.85% [2][3].

Market Overview - The Shandong state-owned enterprise reform sector experienced a decline of 0.42% on October 20, with Baoding Technology leading the drop [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Top Performers in Shandong State-Owned Enterprises - Chui Mu Co., Ltd. (002083) saw a significant increase of 10.00%, closing at 6.16 with a trading volume of 481,000 shares and a transaction value of 296 million [1] - Lu Xin Investment (600783) rose by 6.25%, closing at 14.10 with a trading volume of 226,200 shares and a transaction value of 314 million [1] - Bo Shen Co., Ltd. (002282) increased by 4.31%, closing at 7.50 with a trading volume of 152,800 shares and a transaction value of 113 million [1] Underperformers in Shandong State-Owned Enterprises - Baoding Technology (002552) experienced a decline of 8.88%, closing at 17.04 with a trading volume of 381,600 shares and a transaction value of 659 million [2] - Shandong Gold (600547) fell by 6.34%, closing at 37.94 with a trading volume of 816,300 shares and a transaction value of 3.132 billion [2] - Dongjie Intelligent (300486) decreased by 3.48%, closing at 20.27 with a trading volume of 257,000 shares and a transaction value of 526 million [2] Capital Flow Analysis - The Shandong state-owned enterprise reform sector saw a net outflow of 543 million from institutional investors, while retail investors contributed a net inflow of 770 million [2][3] - Notable net inflows from retail investors were observed in several stocks, including Chui Mu Co., Ltd. (002083) with a net inflow of 72.05 million [3] - Conversely, significant net outflows from institutional investors were noted in stocks like Langxin Information (000977) with a net outflow of 61.54 million [3]